Novo Nordisk crashes after data for next gen obesity drug, Eli Lilly spikes
by
Contributor since / Followers
Contributor since / Followers
11 hours ago
hapabapa/iStock Editorial via Getty Images
Novo Nordisk (NVO) shares crashed on Friday, while its rival Eli Lilly (NYSE:LLY) surged after the Danish drugmaker posted late-stage trial data for its next-gen weight loss therapy, CagriSema.
The company said the once-weekly injectable caused up to ~23% of weight loss